Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer: Pharmacokinetic data
Keyword(s):
Phase Ii
◽
2014 ◽
Vol 22
(2)
◽
pp. 235-241
◽
Keyword(s):